ENDRA Life Sciences Reports Quarterly Earnings Miss

The medical technology company fell short of analyst expectations for the quarter.

Apr. 1, 2026 at 2:48am

Got story updates? Submit your updates here. ›

ENDRA Life Sciences (NASDAQ:NDRA), a company focused on developing thermoacoustic ultrasound imaging technology, reported its quarterly earnings results on Tuesday. The company posted earnings per share of ($3.25), missing the analyst consensus estimate of ($1.23) by a wide margin.

Why it matters

ENDRA's thermoacoustic ultrasound technology is designed to improve the safety and outcomes of thermal ablation procedures, but the company's financial performance has struggled as it works to commercialize the innovative platform. This earnings miss raises questions about the near-term outlook for the business.

The details

ENDRA reported a loss of $3.25 per share for the quarter, significantly worse than the $1.23 per share loss that analysts had expected. The company's stock price fell $0.03, or 0.6%, to $4.65 on the news. ENDRA's shares have traded in a range of $2.90 to $11.96 over the past 52 weeks, with a current market capitalization of $3.49 million.

  • ENDRA Life Sciences reported its quarterly earnings on Tuesday, April 1, 2026.
  • The company's stock price closed at $4.65 on the day of the earnings release.

The players

ENDRA Life Sciences, Inc.

A medical technology company headquartered in Ann Arbor, Michigan that focuses on the development and commercialization of Thermoacoustic Enhanced Ultrasound (TAEUS) imaging technology.

Got photos? Submit your photos here. ›

The takeaway

ENDRA's significant earnings miss raises concerns about the company's ability to successfully commercialize its thermoacoustic ultrasound technology and achieve profitability in the near term. Investors will be closely watching the company's progress as it works to bring its innovative imaging platform to market.